Artificial intelligence is reshaping healthcare, and H2U has decided to be proactive. The company has announced plans to list on the Innovation Board next July, betting on the opportunities offered by AI applied to health data. The move goes beyond finance: it raises strategic questions about sensitive data management and the deployment architectures best suited to a sector where privacy is non-negotiable.

Digital health records: AI in the service of trust

Health data is among the most sensitive categories. Regulations like GDPR in Europe and data protection laws in Asia impose strict constraints on residency, access, and processing. Any system analyzing medical records must ensure regulatory compliance and—even more challenging—earn the trust of patients and institutions. As a result, the adoption of AI models in the sector has a different inertia compared to marketing or finance: errors are not just a business cost but a health risk.

The architectural dilemma: cloud, edge, or on-premise?

Choosing between public cloud, hybrid solutions, and on-premise infrastructure for AI workloads is far from theoretical when dealing with health data. The cloud offers scalability and lower initial CapEx but moves data control outside the company perimeter—a problem for entities that must account for where and how information is handled. The alternative is local deployment, on self-hosted servers or edge appliances, which enables full sovereignty and the integration of AI models—including LLMs for report analysis or clinical research—directly within hospital networks or labs. The trade-off is measured in TCO: on-premise requires investment in hardware (GPU with generous VRAM, fast storage) and in-house expertise, but eliminates recurring operational costs and the risk of vendor lock-in.

Listing as an accelerator: why the market is betting on health AI

H2U's decision to go public is not isolated. More and more companies operating at the intersection of AI and healthcare are seeking capital to scale, amid growing demand for intelligent automation that outpaces the ability to build reliable infrastructure. Investors watch closely those who can combine clinical expertise with software engineering, but also those who demonstrate a clear strategy for compliance and data management. The Innovation Board listing—typically reserved for companies with technology-based business models—signals that the market recognizes the potential of health AI, provided the regulatory fundamentals are solid.

The AI-RADAR perspective: on-premise stacks and data sovereignty

For those operating in healthcare, on-premise deployment is not a technological fad but a regulatory necessity. AI-RADAR closely tracks the evolution of local LLM stacks, where hardware choices (VRAM capacity, memory bandwidth) and software (serving frameworks, quantization) determine the ability to run powerful models in isolated environments. The H2U story shows how, alongside AI enthusiasm, there is growing awareness that without adequate infrastructure and data control, even the most advanced algorithm cannot find real-world application. The challenge for the coming months will be to translate financial announcements into operational architectures capable of meeting privacy and security constraints.